449 related articles for article (PubMed ID: 28205134)
1. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Short NJ; Jabbour E
Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
[TBL] [Abstract][Full Text] [Related]
2. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
3. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
4. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
[TBL] [Abstract][Full Text] [Related]
5. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
7. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Curran E; Stock W
Blood; 2019 Apr; 133(16):1715-1719. PubMed ID: 30796026
[TBL] [Abstract][Full Text] [Related]
8. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
10. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
12. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
13. MRD in ALL: Optimization and Innovations.
Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
15. Detection and management of minimal residual disease in acute lymphoblastic leukemia.
Schrappe M
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):244-9. PubMed ID: 25696862
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
18. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
Cabannes-Hamy A; Brissot E; Leguay T; Huguet F; Chevallier P; Hunault M; Escoffre-Barbe M; Cluzeau T; Balsat M; Nguyen S; Pasquier F; Alexis M; Lheritier V; Pastoret C; Delabesse E; Clappier E; Dombret H; Boissel N
Haematologica; 2022 Sep; 107(9):2072-2080. PubMed ID: 35263986
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
20. [Clinical application of minimal residual disease detection in childhood acute leukemia].
Cheng YQ; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2018 May; 20(5):416-420. PubMed ID: 29764581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
